Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AO-176 |
Synonyms | |
Therapy Description |
AO-176 is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells and may also stimulate cytotoxic T-cells (PMID: 29873856, PMID: 31879362). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AO-176 | AO176|AO 176 | CD47 Antibody 31 Immune Checkpoint Inhibitor 149 | AO-176 is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells and may also stimulate cytotoxic T-cells (PMID: 29873856, PMID: 31879362). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04445701 | Phase Ib/II | AO-176 AO-176 + Dexamethasone AO-176 + Bortezomib + Dexamethasone | Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | Completed | USA | 0 |
NCT03834948 | Phase I | AO-176 | AO-176 in Multiple Solid Tumor Malignancies | Completed | USA | 0 |